The grades of 8 Pharmaceuticals stocks are better this week, according to the Portfolio Grader database. Every one of these stocks has an “A” (“strong buy”) or “B” overall (“buy”) rating.
Eli Lilly and Company (LLY) is seeing ratings go up from a B last week to a A this week. Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. The company also gets A’s in earnings growth, earnings revisions, earnings momentum, and return on equity. For more information, get Portfolio Grader’s complete analysis of LLY stock.
Akorn, Inc.’s (AKRX) ratings are looking better this week, moving up to a B from last week’s C. Akorn, Inc. engages in the manufacture and marketing of diagnostic and therapeutic ophthalmic pharmaceuticals products, niche hospital drugs, and injectable pharmaceuticals in the United States and internationally. The company also gets A’s in sales growth, earnings growth, earnings momentum, and return on equity. For more information, get Portfolio Grader’s complete analysis of AKRX stock.
This week, Intersect ENT Inc’s (XENT) ratings are up from a C last week to a B. The company also gets A’s in sales growth. For more information, get Portfolio Grader’s complete analysis of XENT stock.
The rating of Horizon Pharma plc (HZNP) moves up this week, rising from a B to a A. Horizon Pharma plc is a biopharmaceutical company that is developing and commercializing innovative medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company also gets A’s in sales growth, earnings revisions, and earnings surprise. For more information, get Portfolio Grader’s complete analysis of HZNP stock.
Nektar Therapeutics (NKTR) shows solid improvement this week. The company’s rating rises from a C to a B. Nektar Therapeutics is a clinical-stage biopharmaceutical company which develops a pipeline of drug candidates that utilize company platforms. For more information, get Portfolio Grader’s complete analysis of NKTR stock.
This is a strong week for SciClone Pharmaceuticals, Inc. (SCLN). The company’s rating climbs to B from the previous week’s C. SciClone Pharmaceuticals, Inc. is a global biopharmaceutical company that acquires, develops, and commercializes specialist-oriented drugs. The company also gets A’s in sales growth, earnings growth, and return on equity. For more information, get Portfolio Grader’s complete analysis of SCLN stock.
Corium International, Inc. (CORI) gets a higher grade this week, advancing from a C last week to a B. The company also gets A’s in earnings surprise and earnings momentum. For more information, get Portfolio Grader’s complete analysis of CORI stock.
This week, Auris Medical Holding AG (EARS) pushes up from a C to a B rating. For more information, get Portfolio Grader’s complete analysis of EARS stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
